Patents by Inventor Donald M. Miller

Donald M. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10370665
    Abstract: Quadruplex-forming guanine-rich nucleic acid sequences are useful in compositions and methods for inhibiting cellular growth and proliferation and inducing cell death. Compositions for treating a patient are provided, including (i) a safe and effective amount of a sequence having at least 80% nucleic acid identity with a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and combinations thereof, and (ii) a carrier, wherein the isolated oligonucleotide forms at least one quadruplex.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: August 6, 2019
    Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Donald M. Miller, Shelia D. Thomas, Alexandra Sokolova, Francine Rezzoug
  • Publication number: 20170067057
    Abstract: Quadruplex-forming guanine-rich nucleic acid sequences are useful in compositions and methods for inhibiting cellular growth and proliferation and inducing cell death. Compositions for treating a patient are provided, including (i) a safe and effective amount of a sequence having at least 80% nucleic acid identity with a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 and combinations thereof, and (ii) a carrier, wherein the isolated oligonucleotide forms at least one quadruplex.
    Type: Application
    Filed: March 4, 2015
    Publication date: March 9, 2017
    Inventors: Donald M. Miller, Shelia D. Thomas, Alexandra Sokolova, Francine Rezzoug
  • Publication number: 20140220013
    Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.
    Type: Application
    Filed: October 21, 2013
    Publication date: August 7, 2014
    Applicant: University of Louisville Research Foundation, Inc.
    Inventors: Paula J. Bates, Donald M. Miller, John Q. Trent, Xiaohua Xu
  • Patent number: 8648051
    Abstract: The present invention provides a method for inhibiting the proliferation of malignant and/or hyperplastic cells in a subject by administering to the subject a therapeutically effective amount of a guanosine rich oligonucleotide. The present invention also provides oligonucleotides which are capable of being specifically bound to a specific cellular protein which is nucleolin and/or nucleolin in nature, which is implicated in the proliferation of cells, specifically malignant and/or hyperplastic cells, and a method for their selection.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: February 11, 2014
    Assignee: Advanced Cancer Therapeutics, LLC
    Inventors: Donald M. Miller, Paula J. Bates, John O. Trent
  • Patent number: 8586717
    Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: November 19, 2013
    Assignee: University of Louisville Research Foundation, Inc
    Inventors: Paula J. Bates, Donald M. Miller, John O. Trent, Xiaohua Xu
  • Patent number: 8410070
    Abstract: Quadruplex-forming guanine-rich nucleic acid sequences are useful in compositions and methods for inhibiting cellular growth and proliferation and inducing cell death. Compositions for treating a patient are provided, including (i) a safe and effective amount of a sequence having at least 80% nucleic acid identity with a guanine-rich promoter gene oligonucleotide (GPGO), and (ii) a carrier, wherein the oligonucleotide forms at least one quadruplex.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: April 2, 2013
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Donald M. Miller, Shelia Diann Thomas, Kara Joyce Sedoris
  • Publication number: 20120237937
    Abstract: Some embodiments of the invention include methods for detecting the presence of cancer in animal tissue in an animal that was administered a labeled molecule. Some of the methods disclosed comprise obtaining an NMR spectrum, an MS spectrum, or both. In some instances, spectra can be taken of a cancer cell extract of the tissue and of a non-cancer cell extract of the tissue. In some embodiments, the amounts of at least one resultant labeled molecule (e.g., a molecule resulting from transformation of the administered labeled molecule) from each extract can be compared to detect the presence of cancer.
    Type: Application
    Filed: June 11, 2010
    Publication date: September 20, 2012
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Teresa Whei-Mei Fan, Andrew Nicholas Lane, Michael Bousamra, Donald M. Miller, Richard M. Higashi
  • Publication number: 20120014942
    Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.
    Type: Application
    Filed: May 26, 2011
    Publication date: January 19, 2012
    Inventors: Paula J. Bates, Donald M. Miller, John O. Trent, Xiaohua Xu
  • Patent number: 8029784
    Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: October 4, 2011
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Paula J. Bates, Donald M. Miller, John O. Trent, Xiaohua Xu
  • Publication number: 20110213019
    Abstract: Quadruplex-forming guanine-rich nucleic acid sequences are useful in compositions and methods for inhibiting cellular growth and proliferation and inducing cell death. Compositions for treating a patient are provided, including (i) a safe and effective amount of a sequence having at least 80% nucleic acid identity with a guanine-rich promoter gene oligonucleotide (GPGO), and (ii) a carrier, wherein the oligonucleotide forms at least one quadruplex.
    Type: Application
    Filed: September 11, 2009
    Publication date: September 1, 2011
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Donald M. Miller, Shelia Diann Thomas, Kara Joyce Sedoris
  • Publication number: 20110178161
    Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic; hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 21, 2011
    Applicant: Antisoma Research Limited
    Inventors: John O. Trent, Paula J. Bates, Donald M. Miller
  • Patent number: 7960540
    Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: June 14, 2011
    Assignee: Advanced Cancer Therapeutics, LLC
    Inventors: John O. Trent, Paula J. Bates, Donald M. Miller
  • Publication number: 20100221280
    Abstract: Compositions for treating papillomavirus (PV) infection in a subject include a PV L2 polypeptide produced from a eukaryotic expression system.
    Type: Application
    Filed: April 21, 2010
    Publication date: September 2, 2010
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Shin-je Ghim, A. Bennett Jenson, Amanda B. Lasnik, Donald M. Miller, Kenneth Palmer, Mark L. Smith
  • Publication number: 20090326047
    Abstract: The present invention provides a method for inhibiting the proliferation of malignant and/or hyperplastic cells in a subject by administering to the subject a therapeutically effective amount of a guanosine rich oligonucleotide. The present invention also provides oligonucleotides which are capable of being specifically bound to a specific cellular protein which is nucleolin and/or nucleolin in nature, which is implicated in the proliferation of cells, specifically malignant and/or hyperplastic cells, and a method for their selection.
    Type: Application
    Filed: October 29, 2004
    Publication date: December 31, 2009
    Inventors: Donald M. Miller, Paula J. Bates, John O. Trent
  • Patent number: 7541150
    Abstract: Methods for the diagnosis of cancer by determining the neoplastic status of a cell by probing the cell plasma membrane for the presence of nucleolin are provided, as are kits to carry out such tests.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: June 2, 2009
    Assignee: University of Louisville Research Foundation, Inc
    Inventors: Donald M. Miller, Paula J. Bates, John O. Trent, Xiaohua Xu
  • Publication number: 20090017009
    Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.
    Type: Application
    Filed: March 4, 2008
    Publication date: January 15, 2009
    Inventors: Paula J. Bates, Donald M. Miller, John O. Trent, Xiaohua Xu
  • Publication number: 20080318889
    Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
    Type: Application
    Filed: October 31, 2007
    Publication date: December 25, 2008
    Applicant: Antisoma Research Limited
    Inventors: John O. Trent, Paula J. Bates, Donald M. Miller
  • Publication number: 20080318888
    Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
    Type: Application
    Filed: October 31, 2007
    Publication date: December 25, 2008
    Applicant: Antisoma Research Limited
    Inventors: John O. Trent, Paula J. Bates, Donald M. Miller
  • Publication number: 20080318890
    Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
    Type: Application
    Filed: October 31, 2007
    Publication date: December 25, 2008
    Applicant: Antisoma Research Limited
    Inventors: John O. Trent, Paula J. Bates, Donald M. Miller
  • Publication number: 20080318887
    Abstract: Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and/or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.
    Type: Application
    Filed: October 31, 2007
    Publication date: December 25, 2008
    Applicant: Antisoma Research Limited
    Inventors: John O. Trent, Paula J. Bates, Donald M. Miller